208 related articles for article (PubMed ID: 34371033)
1. Antisense oligonucleotide-mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice.
Bell TA; Liu M; Donner AJ; Lee RG; Mullick AE; Crooke RM
J Lipid Res; 2021; 62():100101. PubMed ID: 34371033
[TBL] [Abstract][Full Text] [Related]
2. Angiopoietin-like 3 inhibition of endothelial lipase is not modulated by angiopoietin-like 8.
Sylvers-Davie KL; Segura-Roman A; Salvi AM; Schache KJ; Davies BSJ
J Lipid Res; 2021; 62():100112. PubMed ID: 34461133
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
[TBL] [Abstract][Full Text] [Related]
4. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
[TBL] [Abstract][Full Text] [Related]
5. ANGPTL3 is a novel HDL component that regulates HDL function.
Yang L; Wang Y; Xu Y; Li K; Yin R; Zhang L; Wang D; Wei L; Lang J; Cheng Y; Wang L; Ke J; Zhao D
J Transl Med; 2024 Mar; 22(1):263. PubMed ID: 38462608
[TBL] [Abstract][Full Text] [Related]
6. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase.
Shimamura M; Matsuda M; Yasumo H; Okazaki M; Fujimoto K; Kono K; Shimizugawa T; Ando Y; Koishi R; Kohama T; Sakai N; Kotani K; Komuro R; Ishida T; Hirata K; Yamashita S; Furukawa H; Shimomura I
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):366-72. PubMed ID: 17110602
[TBL] [Abstract][Full Text] [Related]
7. Angiopoietin-Like 3: From Discovery to Therapeutic Gene Editing.
Wang X; Musunuru K
JACC Basic Transl Sci; 2019 Oct; 4(6):755-762. PubMed ID: 31709322
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
9. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
[TBL] [Abstract][Full Text] [Related]
10. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.
Gusarova V; Alexa CA; Wang Y; Rafique A; Kim JH; Buckler D; Mintah IJ; Shihanian LM; Cohen JC; Hobbs HH; Xin Y; Valenzuela DM; Murphy AJ; Yancopoulos GD; Gromada J
J Lipid Res; 2015 Jul; 56(7):1308-17. PubMed ID: 25964512
[TBL] [Abstract][Full Text] [Related]
11. ANGPTL3 (Angiopoietin-Like 3) Preferentially Resides on High-Density Lipoprotein in the Human Circulation, Affecting Its Activity.
Kraaijenhof JM; Tromp TR; Nurmohamed NS; Reeskamp LF; Langenkamp M; Levels JHM; Boekholdt SM; Wareham NJ; Hoekstra M; Stroes ESG; Hovingh GK; Grefhorst A
J Am Heart Assoc; 2023 Nov; 12(21):e030476. PubMed ID: 37889183
[TBL] [Abstract][Full Text] [Related]
12. Angiopoietin-like 3: An important protein in regulating lipoprotein levels.
Burks KH; Basu D; Goldberg IJ; Stitziel NO
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101688. PubMed ID: 35999139
[TBL] [Abstract][Full Text] [Related]
13. Angiopoietin-like 3 in lipoprotein metabolism.
Kersten S
Nat Rev Endocrinol; 2017 Dec; 13(12):731-739. PubMed ID: 28984319
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus.
Liu S; Ke J; Feng X; Wang Z; Wang X; Yang L; Zhao D
J Diabetes Res; 2024; 2024():2431441. PubMed ID: 38577301
[TBL] [Abstract][Full Text] [Related]
15. Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients.
Zhao D; Yang LY; Wang XH; Yuan SS; Yu CG; Wang ZW; Lang JN; Feng YM
Cardiovasc Diabetol; 2016 Sep; 15(1):132. PubMed ID: 27620179
[TBL] [Abstract][Full Text] [Related]
16. Relationship between Serum Angiopoietin-like Proteins 3 and 8 and Atherogenic Lipid Biomarkers in Non-Diabetic Adults Depends on Gender and Obesity.
Murawska K; Krintus M; Kuligowska-Prusinska M; Szternel L; Stefanska A; Sypniewska G
Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959891
[TBL] [Abstract][Full Text] [Related]
17. Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects.
Lupo MG; Ferri N
J Cardiovasc Dev Dis; 2018 Jul; 5(3):. PubMed ID: 30011918
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice.
Bell TA; Graham MJ; Lee RG; Mullick AE; Fu W; Norris D; Crooke RM
J Lipid Res; 2013 Oct; 54(10):2647-57. PubMed ID: 23801661
[TBL] [Abstract][Full Text] [Related]
19. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.
Luo F; Das A; Khetarpal SA; Fang Z; Zelniker TA; Rosenson RS; Qamar A
Trends Cardiovasc Med; 2024 May; 34(4):215-222. PubMed ID: 36746257
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-independent regulation of reverse cholesterol transport by liver X receptors.
Breevoort SR; Angdisen J; Schulman IG
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1650-60. PubMed ID: 24947527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
